
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
National health trends for 2025 show a complex mix of improved cancer screenings alongside rising chronic conditions and affordability gaps.
The United Health Foundation’s 2025 annual report, titled






